Haier Biomedical was established in 2005 and listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange in 2019 (stock code: 688139). The Company aims to create the best user experience for a wide range of user groups such as hospitals, biotechnology enterprises, universities & colleges, scientific research institutions, centres for disease control and prevention, plasma stations, and primary public health authorities. The Company mainly engages in two major business fields: life sciences and medical innovation.